Trial Profile
Phase 2b Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of a Subcutaneous Prophylaxis Treatment Regimen of CB2679d, in Adult Subjects With Hemophilia B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2023
Price :
$35
*
At a glance
- Drugs Dalcinonacog alfa (Primary) ; Dalcinonacog alfa
- Indications Haemophilia B
- Focus Therapeutic Use
- Sponsors Catalyst Biosciences
- 12 Jun 2023 Results supporting dosing regimen selection in adults and perform first in paediatric dose extrapolations using a model based pharmacokinetic (PK) approach of population PK model built using adult data from NCT03186677and NCT03995784, published in the Advances in Therapy
- 06 Aug 2020 According to a Catalyst Biosciences media release, timeline for this trial is subject to the readiness of trial sites and potential effects of COVID-19 on clinical trial execution.
- 15 Jun 2020 Primary endpoint has been met. (Evaluate the dose required to achieve steady-state FIX levels 12%), according to a Catalyst Biosciences media release.